Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.

Vasc Health Risk Manag · 2010 · PMC2941781 · PMID 20859539

Europe PMC DOI

hedged sentence

0.0950

closest p · 1.9× alpha

0.0950

boldest claim

The sentences

did not reach statistical significanceP = 0.095so close (0.05 < p ≤ 0.1)

The primary endpoint (composite of death, MI, stroke, leg amputation, acute coronary syndrome, cardiac bypass, or leg revascularization) was reduced by 10% but this did not reach statistical significance because of an increase in leg revascularization (HR 0.90, 95% CI 0.80–1.02; P = 0.095).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.